Atlas Genetics Raises $35m In Series D Fundraising

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech.

Cue Biopharma Debuts With $26 Million in Invested Capital to Develop Next-Generation Biologics to...

Two years after being founded, Cambridge, Massachusetts, upstart Cue Biopharma has raised $26 million to help advance its work using biologics to target T cell receptors to help patients’ immune systems defeat cancer and autoimmune diseases.

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

Life Science Leaders Celebrate Global Partnerships During WuXi Global Forum 2018

More than 2,000 life science industry insiders around the globe participated in the WuXi Global Forum on Jan. 9, 2018 during the annual J.P....

WuXi Global Forum 2018